Airways reactivity in patients with CF

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology

Background:

• Airway hyperresponsiveness (AHR) is characterized by increased bronchial smooth muscle tone.
• Some cystic fibrosis (CF) patients exhibit AHR, often linked to co-existing asthma.
• However, many CF patients show bronchodilator responsiveness without typical asthma symptoms or responses.

Purpose of the Study:

• To differentiate airway hyperresponsiveness patterns in cystic fibrosis patients.
• To investigate the underlying mechanisms and clinical significance of AHR in CF.
• To evaluate the role of bronchodilators in routine CF care.

Main Methods:

• Comparative analysis of airway responses in CF patients with and without asthma.
• Assessment of responses to inhaled beta-2 agonists, corticosteroids, exercise, histamine, and ipratropium.
• Evaluation of clinical responses to bronchodilator therapy.

Main Results:

• CF patients without asthma show bronchodilator responsiveness, unlike asthmatics.
• Exercise can cause bronchodilation in CF patients lacking asthma symptoms.
• Histamine-induced bronchospasm in non-asthmatic CF patients is reversed by ipratropium, unlike in asthmatic CF patients.
• Vagal mediation due to airway damage is suggested as the mechanism for AHR in CF.

Conclusions:

• Airway hyperresponsiveness in CF appears distinct from asthma, potentially vagally mediated by lung disease.
• Routine bronchodilator use in CF care is controversial and lacks strong clinical evidence unless asthma is present.
• Bronchodilators may be justified in CF if they lead to subjective symptom improvement or enhanced sputum production before physical therapy.